New Brunswick, NJ (WBAP/KLIF News) – Johnson and Johnson is optimistic about the efficacy of its COVID-19 vaccine booster shot.
The pharmaceutical company on Wednesday announced its booster shot generated a “promising immune response” in early stage clinical trials.
According to data from the study, recipients of the shot created virus-fighting antibodies “nine-fold higher” than those who got one shot four weeks after the first dose.
The news comes after J & J reported interim Phase 1/2a data published in the New England Journal of Medicine in July, that trials demonstrated neutralizing antibody responses generated by its vaccine were strong and stable through eight months after immunization.
New data from the booster trials show the high efficacy rate were observed in participants between ages 18 and 55 and in those 65 years and older who received a lower booster dose.
“We have established that a single shot of our COVID-19 vaccine generates a strong and robust immune responses that are durable and persistent through eight months. With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson. “We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination.”
Click here for more information.
The news comes after the U S Center for Disease Control and Prevention recommended COVID-19 vaccine booster shots for immunocompromised citizens.
The booster should be available to everyone later on.
The Johnson and Johnson COVID-19 vaccine is not fully approved by the FDA. The company said it would start the application process later this year.
Pfizer BioNTech became the first in the United States to get full FDA approval for its vaccine. Moderna has already started the application process.
Copyright 2021. WBAP/KLIF News. All Rights Reserved.
